Keytruda (pembrolizumab) has been recommended for approval in the European Union (EU) to treat adults and children, 3 years and older, with relapsed or refractory classical Hodgkin’s lymphoma (cHL) whose disease failed to respond to autologous stem cell transplant (ASCT) or who received at least two prior therapies when ineligible for ASCT. The therapy is already available in Europe to adults with relapsed or refractory cHL whose disease progressed following ASCT and Adcetris (brentuximab vedotin), or…
You must be logged in to read/download the full post.
The post Keytruda Closer to Expanded EU Approval for Resistant Hodgkin’s Lymphoma appeared first on BioNewsFeeds.